Benefits
Insulin sensitivity: studied mainly in people with type 2 diabetes
Chromium is an essential trace mineral that appears to play a part in how insulin signals cells to take up glucose. What the cited studies actually show is narrower. A randomized, placebo-controlled trial in people with type 2 diabetes reported improved insulin sensitivity and less body weight gain. A systematic review and meta-analysis of chromium in people with diabetes reported favourable effects on blood sugar control, averaging about 0.55% lower HbA1c and 1.15 mmol/L lower fasting glucose, and found no increase in side effects at usual doses. Both were done in people with a diagnosed condition who were being treated by a doctor, so they say little about what chromium does for someone healthy. Chromium is not a treatment for diabetes or any other disease, and none of the cited studies tested it as one.
Appetite and carbohydrate cravings: one small 8 week trial
One randomized, double-blind, placebo-controlled trial using Chromax reported reduced food intake, hunger and fat cravings in 42 overweight women who crave carbohydrates, over 8 weeks. That is a single small trial in women only, and it measured appetite rather than weight lost or kept off. The cited studies did not test emotional eating or binge eating. The idea that chromium works by shifting tryptophan into the brain to change serotonin is a proposed explanation, not something these trials measured.
Body weight: about 1 kg in a meta analysis, and the authors doubted it mattered
None of the studies cited on this page measured lean muscle mass or body fat, so a lean-mass-sparing effect is not supported here. What was measured was scale weight. A meta-analysis of randomized trials of chromium picolinate for weight loss found an average of about 1.1 kg more weight lost than placebo, and the authors concluded that the clinical relevance of the effect is debatable and that the lack of robustness means the result has to be interpreted with caution. A separate trial in people with type 2 diabetes reported less weight gain than placebo, again in a patient group being treated by a doctor.
Mechanism of action
Chromodulin / LMWCr insulin receptor sensitization
Chromium activates low-molecular-weight chromium-binding substance (chromodulin/LMWCr) — a chromium-containing oligopeptide that amplifies insulin receptor tyrosine kinase activity when insulin binds. This chromodulin model is the leading laboratory explanation for how chromium might help cells take up glucose, but it is still debated among researchers and it was not measured in any of the human trials cited here. Picolinic acid binds the chromium and is thought to help it cross the gut wall. That is a laboratory and theoretical picture rather than something the human trials cited here tested, and none of those trials compared Chromax with another form of chromium, so a better-absorption claim is not supported on this page.
Clinical trials
A summary of the published meta-analyses and randomized trials of chromium picolinate, covering blood sugar markers in people with diagnosed type 2 diabetes and body weight in overweight adults.
Mostly adults with diagnosed type 2 diabetes; the weight-loss meta-analysis pooled trials in overweight adults, and the one appetite trial enrolled 42 overweight women who crave carbohydrates.
In people with type 2 diabetes, a meta-analysis reported favourable effects on blood sugar control, averaging about 0.55% lower HbA1c and 1.15 mmol/L lower fasting glucose, with no increase in side effects at usual doses. For body weight, a meta-analysis of randomized trials found about 1.1 kg more weight lost than placebo (95% confidence interval 1.8 to 0.4 kg), largely driven by a single trial, and the authors wrote that the clinical relevance of the effect is debatable. Outside of diabetes, the human evidence cited here is one small 8 week appetite trial. Note: pooled analyses on chromium have been mixed — some show benefit, others null; heterogeneity in formulations and populations is high. Industry-funded trials tended to show larger effects than independent trials.